Position in NVS
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$275,561
-$36,243 QoQ
Shares Held
1,804
-47.5% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
11 quarters on record
Voting authority
Sole 45%
Shared 0%
None 55%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Linscomb Wealth, Inc. holds $62,600,297 across 7 Drug Manufacturers - General names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABBV |
AbbVie Inc.
|
70,722 | $17,796,484 | |
| 2 | JNJ |
Johnson & Johnson
|
59,468 | $15,103,087 | |
| 3 | MRK |
Merck & Co., Inc.
|
92,395 | $11,872,757 | |
| 4 | AMGN |
Amgen Inc
|
29,620 | $10,725,994 | |
| 5 | PFE |
Pfizer Inc
|
209,174 | $5,036,909 | |
| 6 | LLY |
ELI LILLY & Co
|
1,056 | $1,266,598 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
6,320 | $798,468 |
All Filings in NVS
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $275,561 | 1,804 | Shares | Sole | 2026-05-11 | |
| 2022-12-31 | $311,804 | 3,437 | Shares | Sole | 2023-02-14 | |
| 2022-03-31 | $301,596 | 3,437 | Shares | Sole | 2022-05-17 | |
| 2021-12-31 | $283,927 | 3,246 | Shares | Sole | 2022-02-10 | |
| 2021-09-30 | $265,621 | 3,248 | Shares | Sole | 2021-11-03 | |
| 2021-06-30 | $292,697 | 3,208 | Shares | Sole | 2021-08-10 | |
| 2021-03-31 | $289,349 | 3,385 | Shares | Sole | 2021-05-12 | |
| 2020-12-31 | $328,333 | 3,477 | Shares | Sole | 2021-02-11 | |
| 2020-09-30 | $298,359 | 3,431 | Shares | Sole | 2020-11-13 | |
| 2020-06-30 | $302,109 | 3,459 | Shares | Sole | 2020-08-11 | |
| 2020-03-31 | $297,397 | 3,607 | Shares | Sole | 2020-05-11 | |
| No filing history on record for this holder in this stock. | ||||||